Loading stock data…
$20.26+0.07 (+0.35%)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NewAmsterdam Pharma Company N.V. in the Healthcare sector is trading at $20.26 with a market capitalization of $2.9B. Wall Street consensus targets $49.35 (15 analysts), implying a +143.6% move over the next 12 months. The stock is currently near its 52-week low of $19.88, remaining 33.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.70M↑ | $3.04M↑ | $32,000↓ | $348,000↓ | $19.14M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$64.86M↓ | -$58.42M↑ | -$65.98M↓ | -$55.14M↓ | -$35.63M |
| Net Income | -$64.14M↓ | -$48.44M↑ | -$74.92M↓ | -$72.00M↓ | -$17.36M |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP)...